Loading…
Enrofloxacin-The Ruthless Killer of Eukaryotic Cells or the Last Hope in the Fight against Bacterial Infections?
Enrofloxacin is a compound that originates from a group of fluoroquinolones that is widely used in veterinary medicine as an antibacterial agent (this antibiotic is not approved for use as a drug in humans). It reveals strong antibiotic activity against both Gram-positive and Gram-negative bacteria,...
Saved in:
Published in: | International journal of molecular sciences 2022-03, Vol.23 (7), p.3648 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c521t-b85bbecd0357cacbd99c4a0eb522ae448656093c3c4ff8b3425fd0c45a388d143 |
---|---|
cites | cdi_FETCH-LOGICAL-c521t-b85bbecd0357cacbd99c4a0eb522ae448656093c3c4ff8b3425fd0c45a388d143 |
container_end_page | |
container_issue | 7 |
container_start_page | 3648 |
container_title | International journal of molecular sciences |
container_volume | 23 |
creator | Grabowski, Łukasz Gaffke, Lidia Pierzynowska, Karolina Cyske, Zuzanna Choszcz, Marta Węgrzyn, Grzegorz Węgrzyn, Alicja |
description | Enrofloxacin is a compound that originates from a group of fluoroquinolones that is widely used in veterinary medicine as an antibacterial agent (this antibiotic is not approved for use as a drug in humans). It reveals strong antibiotic activity against both Gram-positive and Gram-negative bacteria, mainly due to the inhibition of bacterial gyrase and topoisomerase IV enzymatic actions. The high efficacy of this molecule has been demonstrated in the treatment of various animals on farms and other locations. However, the use of enrofloxacin causes severe adverse effects, including skeletal, reproductive, immune, and digestive disorders. In this review article, we present in detail and discuss the advantageous and disadvantageous properties of enrofloxacin, showing the benefits and risks of the use of this compound in veterinary medicine. Animal health and the environmental effects of this stable antibiotic (with half-life as long as 3-9 years in various natural environments) are analyzed, as are the interesting properties of this molecule that are expressed when present in complexes with metals. Recommendations for further research on enrofloxacin are also proposed. |
doi_str_mv | 10.3390/ijms23073648 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_5f73016c9cf5457bb4d92d4e9a5c99b9</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_5f73016c9cf5457bb4d92d4e9a5c99b9</doaj_id><sourcerecordid>2649589487</sourcerecordid><originalsourceid>FETCH-LOGICAL-c521t-b85bbecd0357cacbd99c4a0eb522ae448656093c3c4ff8b3425fd0c45a388d143</originalsourceid><addsrcrecordid>eNpdkk1vEzEQhleIipbCjTOyxKUHtnj9sWtfQCVKaUQkJFTOlu21EwfHDrYXtf8ek5Qq5eTRzKNHfkfTNG86eIkxhx_cZpsRhgPuCXvWnHUEoRbCfnh-VJ82L3PeQIgwovxFc4opgRzC4azZzUOK1sc7qV1ob9cGfJ_K2pucwVfnvUkgWjCffsp0H4vTYGa8zyAmUCq6lLmAm7gzwIV949qt1gXIlXShTj5LXUxy0oNFsEYXF0P-9Ko5sdJn8_rhPW9-XM9vZzft8tuXxexq2WqKutIqRpUyeoSYDlpqNXKuiYRGUYSkIYT1tIcca6yJtUxhgqgdoSZUYsbGjuDzZnHwjlFuxC65bY0gonRi34hpJWSqibwR1A4Ydr3m2lJCB6XIyNFIDJdUc654dX08uHaT2ppRm1CS9E-kTyfBrcUq_haMc0ZJXwUXD4IUf00mF7F1WddVymDilAXqCaeMEzZU9N1_6CZOKdRV7SnYMdp3lXp_oHSKOSdjHz_TQfH3LMTxWVT87XGAR_jfHeA_i-i0aw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2649018561</pqid></control><display><type>article</type><title>Enrofloxacin-The Ruthless Killer of Eukaryotic Cells or the Last Hope in the Fight against Bacterial Infections?</title><source>Open Access: PubMed Central</source><source>Publicly Available Content (ProQuest)</source><creator>Grabowski, Łukasz ; Gaffke, Lidia ; Pierzynowska, Karolina ; Cyske, Zuzanna ; Choszcz, Marta ; Węgrzyn, Grzegorz ; Węgrzyn, Alicja</creator><creatorcontrib>Grabowski, Łukasz ; Gaffke, Lidia ; Pierzynowska, Karolina ; Cyske, Zuzanna ; Choszcz, Marta ; Węgrzyn, Grzegorz ; Węgrzyn, Alicja</creatorcontrib><description>Enrofloxacin is a compound that originates from a group of fluoroquinolones that is widely used in veterinary medicine as an antibacterial agent (this antibiotic is not approved for use as a drug in humans). It reveals strong antibiotic activity against both Gram-positive and Gram-negative bacteria, mainly due to the inhibition of bacterial gyrase and topoisomerase IV enzymatic actions. The high efficacy of this molecule has been demonstrated in the treatment of various animals on farms and other locations. However, the use of enrofloxacin causes severe adverse effects, including skeletal, reproductive, immune, and digestive disorders. In this review article, we present in detail and discuss the advantageous and disadvantageous properties of enrofloxacin, showing the benefits and risks of the use of this compound in veterinary medicine. Animal health and the environmental effects of this stable antibiotic (with half-life as long as 3-9 years in various natural environments) are analyzed, as are the interesting properties of this molecule that are expressed when present in complexes with metals. Recommendations for further research on enrofloxacin are also proposed.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms23073648</identifier><identifier>PMID: 35409007</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Acids ; adverse effects ; Animal health ; Animals ; Anti-Bacterial Agents - pharmacology ; Anti-Bacterial Agents - therapeutic use ; Antibacterial agents ; antibiotic ; Antibiotics ; Antiinfectives and antibacterials ; Bacteria ; Bacterial infections ; Bacterial Infections - drug therapy ; Bacterial Infections - veterinary ; Bioavailability ; Caretta caretta ; Chelonia mydas ; DNA topoisomerase IV ; efficacy ; Enrofloxacin ; Enrofloxacin - pharmacology ; Enrofloxacin - therapeutic use ; Environmental effects ; Enzymes ; Eukaryotic Cells ; Fluoroquinolones ; Fluoroquinolones - pharmacology ; Fluoroquinolones - therapeutic use ; Gene expression ; Gram-Negative Bacteria ; Gram-Positive Bacteria ; Metabolism ; Metabolites ; Metals ; Oral administration ; Pharmacokinetics ; Polyvinyl alcohol ; Review ; safety ; Streptococcus infections ; toxicity ; Veterinary medicine</subject><ispartof>International journal of molecular sciences, 2022-03, Vol.23 (7), p.3648</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c521t-b85bbecd0357cacbd99c4a0eb522ae448656093c3c4ff8b3425fd0c45a388d143</citedby><cites>FETCH-LOGICAL-c521t-b85bbecd0357cacbd99c4a0eb522ae448656093c3c4ff8b3425fd0c45a388d143</cites><orcidid>0000-0003-4042-7466 ; 0000-0003-3746-8726 ; 0000-0002-3073-2814 ; 0000-0002-0820-7204 ; 0000-0003-3634-6567</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2649018561/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2649018561?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,74998</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35409007$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Grabowski, Łukasz</creatorcontrib><creatorcontrib>Gaffke, Lidia</creatorcontrib><creatorcontrib>Pierzynowska, Karolina</creatorcontrib><creatorcontrib>Cyske, Zuzanna</creatorcontrib><creatorcontrib>Choszcz, Marta</creatorcontrib><creatorcontrib>Węgrzyn, Grzegorz</creatorcontrib><creatorcontrib>Węgrzyn, Alicja</creatorcontrib><title>Enrofloxacin-The Ruthless Killer of Eukaryotic Cells or the Last Hope in the Fight against Bacterial Infections?</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>Enrofloxacin is a compound that originates from a group of fluoroquinolones that is widely used in veterinary medicine as an antibacterial agent (this antibiotic is not approved for use as a drug in humans). It reveals strong antibiotic activity against both Gram-positive and Gram-negative bacteria, mainly due to the inhibition of bacterial gyrase and topoisomerase IV enzymatic actions. The high efficacy of this molecule has been demonstrated in the treatment of various animals on farms and other locations. However, the use of enrofloxacin causes severe adverse effects, including skeletal, reproductive, immune, and digestive disorders. In this review article, we present in detail and discuss the advantageous and disadvantageous properties of enrofloxacin, showing the benefits and risks of the use of this compound in veterinary medicine. Animal health and the environmental effects of this stable antibiotic (with half-life as long as 3-9 years in various natural environments) are analyzed, as are the interesting properties of this molecule that are expressed when present in complexes with metals. Recommendations for further research on enrofloxacin are also proposed.</description><subject>Acids</subject><subject>adverse effects</subject><subject>Animal health</subject><subject>Animals</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibacterial agents</subject><subject>antibiotic</subject><subject>Antibiotics</subject><subject>Antiinfectives and antibacterials</subject><subject>Bacteria</subject><subject>Bacterial infections</subject><subject>Bacterial Infections - drug therapy</subject><subject>Bacterial Infections - veterinary</subject><subject>Bioavailability</subject><subject>Caretta caretta</subject><subject>Chelonia mydas</subject><subject>DNA topoisomerase IV</subject><subject>efficacy</subject><subject>Enrofloxacin</subject><subject>Enrofloxacin - pharmacology</subject><subject>Enrofloxacin - therapeutic use</subject><subject>Environmental effects</subject><subject>Enzymes</subject><subject>Eukaryotic Cells</subject><subject>Fluoroquinolones</subject><subject>Fluoroquinolones - pharmacology</subject><subject>Fluoroquinolones - therapeutic use</subject><subject>Gene expression</subject><subject>Gram-Negative Bacteria</subject><subject>Gram-Positive Bacteria</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>Metals</subject><subject>Oral administration</subject><subject>Pharmacokinetics</subject><subject>Polyvinyl alcohol</subject><subject>Review</subject><subject>safety</subject><subject>Streptococcus infections</subject><subject>toxicity</subject><subject>Veterinary medicine</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkk1vEzEQhleIipbCjTOyxKUHtnj9sWtfQCVKaUQkJFTOlu21EwfHDrYXtf8ek5Qq5eTRzKNHfkfTNG86eIkxhx_cZpsRhgPuCXvWnHUEoRbCfnh-VJ82L3PeQIgwovxFc4opgRzC4azZzUOK1sc7qV1ob9cGfJ_K2pucwVfnvUkgWjCffsp0H4vTYGa8zyAmUCq6lLmAm7gzwIV949qt1gXIlXShTj5LXUxy0oNFsEYXF0P-9Ko5sdJn8_rhPW9-XM9vZzft8tuXxexq2WqKutIqRpUyeoSYDlpqNXKuiYRGUYSkIYT1tIcca6yJtUxhgqgdoSZUYsbGjuDzZnHwjlFuxC65bY0gonRi34hpJWSqibwR1A4Ydr3m2lJCB6XIyNFIDJdUc654dX08uHaT2ppRm1CS9E-kTyfBrcUq_haMc0ZJXwUXD4IUf00mF7F1WddVymDilAXqCaeMEzZU9N1_6CZOKdRV7SnYMdp3lXp_oHSKOSdjHz_TQfH3LMTxWVT87XGAR_jfHeA_i-i0aw</recordid><startdate>20220326</startdate><enddate>20220326</enddate><creator>Grabowski, Łukasz</creator><creator>Gaffke, Lidia</creator><creator>Pierzynowska, Karolina</creator><creator>Cyske, Zuzanna</creator><creator>Choszcz, Marta</creator><creator>Węgrzyn, Grzegorz</creator><creator>Węgrzyn, Alicja</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-4042-7466</orcidid><orcidid>https://orcid.org/0000-0003-3746-8726</orcidid><orcidid>https://orcid.org/0000-0002-3073-2814</orcidid><orcidid>https://orcid.org/0000-0002-0820-7204</orcidid><orcidid>https://orcid.org/0000-0003-3634-6567</orcidid></search><sort><creationdate>20220326</creationdate><title>Enrofloxacin-The Ruthless Killer of Eukaryotic Cells or the Last Hope in the Fight against Bacterial Infections?</title><author>Grabowski, Łukasz ; Gaffke, Lidia ; Pierzynowska, Karolina ; Cyske, Zuzanna ; Choszcz, Marta ; Węgrzyn, Grzegorz ; Węgrzyn, Alicja</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c521t-b85bbecd0357cacbd99c4a0eb522ae448656093c3c4ff8b3425fd0c45a388d143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Acids</topic><topic>adverse effects</topic><topic>Animal health</topic><topic>Animals</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibacterial agents</topic><topic>antibiotic</topic><topic>Antibiotics</topic><topic>Antiinfectives and antibacterials</topic><topic>Bacteria</topic><topic>Bacterial infections</topic><topic>Bacterial Infections - drug therapy</topic><topic>Bacterial Infections - veterinary</topic><topic>Bioavailability</topic><topic>Caretta caretta</topic><topic>Chelonia mydas</topic><topic>DNA topoisomerase IV</topic><topic>efficacy</topic><topic>Enrofloxacin</topic><topic>Enrofloxacin - pharmacology</topic><topic>Enrofloxacin - therapeutic use</topic><topic>Environmental effects</topic><topic>Enzymes</topic><topic>Eukaryotic Cells</topic><topic>Fluoroquinolones</topic><topic>Fluoroquinolones - pharmacology</topic><topic>Fluoroquinolones - therapeutic use</topic><topic>Gene expression</topic><topic>Gram-Negative Bacteria</topic><topic>Gram-Positive Bacteria</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>Metals</topic><topic>Oral administration</topic><topic>Pharmacokinetics</topic><topic>Polyvinyl alcohol</topic><topic>Review</topic><topic>safety</topic><topic>Streptococcus infections</topic><topic>toxicity</topic><topic>Veterinary medicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Grabowski, Łukasz</creatorcontrib><creatorcontrib>Gaffke, Lidia</creatorcontrib><creatorcontrib>Pierzynowska, Karolina</creatorcontrib><creatorcontrib>Cyske, Zuzanna</creatorcontrib><creatorcontrib>Choszcz, Marta</creatorcontrib><creatorcontrib>Węgrzyn, Grzegorz</creatorcontrib><creatorcontrib>Węgrzyn, Alicja</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Grabowski, Łukasz</au><au>Gaffke, Lidia</au><au>Pierzynowska, Karolina</au><au>Cyske, Zuzanna</au><au>Choszcz, Marta</au><au>Węgrzyn, Grzegorz</au><au>Węgrzyn, Alicja</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Enrofloxacin-The Ruthless Killer of Eukaryotic Cells or the Last Hope in the Fight against Bacterial Infections?</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2022-03-26</date><risdate>2022</risdate><volume>23</volume><issue>7</issue><spage>3648</spage><pages>3648-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>Enrofloxacin is a compound that originates from a group of fluoroquinolones that is widely used in veterinary medicine as an antibacterial agent (this antibiotic is not approved for use as a drug in humans). It reveals strong antibiotic activity against both Gram-positive and Gram-negative bacteria, mainly due to the inhibition of bacterial gyrase and topoisomerase IV enzymatic actions. The high efficacy of this molecule has been demonstrated in the treatment of various animals on farms and other locations. However, the use of enrofloxacin causes severe adverse effects, including skeletal, reproductive, immune, and digestive disorders. In this review article, we present in detail and discuss the advantageous and disadvantageous properties of enrofloxacin, showing the benefits and risks of the use of this compound in veterinary medicine. Animal health and the environmental effects of this stable antibiotic (with half-life as long as 3-9 years in various natural environments) are analyzed, as are the interesting properties of this molecule that are expressed when present in complexes with metals. Recommendations for further research on enrofloxacin are also proposed.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>35409007</pmid><doi>10.3390/ijms23073648</doi><orcidid>https://orcid.org/0000-0003-4042-7466</orcidid><orcidid>https://orcid.org/0000-0003-3746-8726</orcidid><orcidid>https://orcid.org/0000-0002-3073-2814</orcidid><orcidid>https://orcid.org/0000-0002-0820-7204</orcidid><orcidid>https://orcid.org/0000-0003-3634-6567</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1422-0067 |
ispartof | International journal of molecular sciences, 2022-03, Vol.23 (7), p.3648 |
issn | 1422-0067 1661-6596 1422-0067 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_5f73016c9cf5457bb4d92d4e9a5c99b9 |
source | Open Access: PubMed Central; Publicly Available Content (ProQuest) |
subjects | Acids adverse effects Animal health Animals Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use Antibacterial agents antibiotic Antibiotics Antiinfectives and antibacterials Bacteria Bacterial infections Bacterial Infections - drug therapy Bacterial Infections - veterinary Bioavailability Caretta caretta Chelonia mydas DNA topoisomerase IV efficacy Enrofloxacin Enrofloxacin - pharmacology Enrofloxacin - therapeutic use Environmental effects Enzymes Eukaryotic Cells Fluoroquinolones Fluoroquinolones - pharmacology Fluoroquinolones - therapeutic use Gene expression Gram-Negative Bacteria Gram-Positive Bacteria Metabolism Metabolites Metals Oral administration Pharmacokinetics Polyvinyl alcohol Review safety Streptococcus infections toxicity Veterinary medicine |
title | Enrofloxacin-The Ruthless Killer of Eukaryotic Cells or the Last Hope in the Fight against Bacterial Infections? |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T21%3A17%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Enrofloxacin-The%20Ruthless%20Killer%20of%20Eukaryotic%20Cells%20or%20the%20Last%20Hope%20in%20the%20Fight%20against%20Bacterial%20Infections?&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Grabowski,%20%C5%81ukasz&rft.date=2022-03-26&rft.volume=23&rft.issue=7&rft.spage=3648&rft.pages=3648-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms23073648&rft_dat=%3Cproquest_doaj_%3E2649589487%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c521t-b85bbecd0357cacbd99c4a0eb522ae448656093c3c4ff8b3425fd0c45a388d143%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2649018561&rft_id=info:pmid/35409007&rfr_iscdi=true |